Navigation Links
Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
Date:11/3/2011

ospective observational studies or to provide further analysis of clinical trial data; our response to questions and requests for additional information including additional pre-clinical or clinical studies from the European Medicines Agency, or EMA, and the Committee for Medicinal Products for Human Use, or CHMP, of the Marketing Authorization Application, or MAA, for Qnexa; the results of external studies to assess the teratogenic risk of topiramate; results of the REMS or cardiovascular outcomes for obesity advisory meetings; the outcome of the second advisory committee meeting for Qnexa; the impact, if any, of the agreement by one of our competitors with an obesity compound to conduct or complete a cardiovascular outcomes study pre-approval; impact on future sales based on specific indication and contraindications contained in the label and extent of the REMS, distribution and patient access program; the FDA's response to the NDA filed for avanafil; our ability to successfully commercialize or establish a marketing partnership for avanafil or our partner's ability to obtain regulatory approval to manufacture and adequately supply avanafil for commercial use; our history of losses and variable quarterly results; substantial competition; risks related to the failure to protect our intellectual property and litigation in which we may become involved; uncertainties of government or third party payer reimbursement; our reliance on sole source suppliers; our limited sales and marketing efforts and our reliance on third parties; failure to continue to develop innovative investigational drug candidates and drugs; risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA or foreign authority regulations; our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; our dependence on the performance of our collaborative partners; the timing of the initiation
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
4. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
5. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
6. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
7. New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
8. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
9. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
10. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
11. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... CAPE TOWN, South Africa , Jan. 23, 2015 ... and distributor of personal protective equipment for all forms ... include the flagship Leatt-Brace® neck brace, announced today that ... minicross racing federation, now requires all riders to wear ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) disclosed ... Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier® will ... Exposition of the American Society of Nephrology (ASN). Dr. ... Director of Nephrology at the Fortis Hospital in New ...
... , MARIETTA, Ga., Oct. 15 Solvay Pharmaceuticals, Inc. ... Delayed-Release Capsules significantly improves a key measure of fat ... pancreatic insufficiency (EPI) due to cystic fibrosis (CF). EPI ... production and/or secretion of pancreatic enzymes that are necessary ...
Cached Medicine Technology:Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference 2Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference 3CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 2CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 3CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 4CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 5CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 6
(Date:1/23/2015)... Hastings and Hastings, a law firm in Arizona that focuses ... representation client review requests for slip and fall accidents in ... the number of slip and fall related accidents that happen ... that said, a large number of injury victims are requesting ... Hastings and Hastings is a personal injury firm in Arizona ...
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has ... the business is showing its latest designs of wedding dresses ... to the company’s CEO, all the fresh new products are ... discounts, up to 80% off. All the clothes from LunaDress ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, AZ ... Alliance (PPHA). The PPHA's passion for others' well-being and ... greats, treated for obstructive sleep apnea (OSA) has propelled them ... in the valley. The most recent plans for an event ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... law, pledges to, fight for consumers, rights ... ... SEATTLE, March 3 RealSelf.com today filed an ... Trademark,Infringement Complaint, denying Lifestyle Lift,s claims and also responding,with ...
... Wash. and LOS ANGELES, March 3 For the ... inc.,(Nasdaq: DSCM ), has enlisted Los Angeles-based women,s ... doubles as a cosmetic case or,fashionable clutch. Customers receive ... product samples from today,s top prestige beauty,brands with a ...
... Using a new tool designed to measure a womans ... the sexual transmission of HIV), researchers at The Miriam Hospital ... methods in the past, and those with casual sexual partners ... peers. , Although a safe and effective microbicide has ...
... Featuring Emmy award-winning composer, Yale professor and African,women,s ... Malkin, Emmy,award-winning composer, together with poet Kim Rosen, ... Conference in Pittsburgh at,the Westin Convention Center on ... health will be the conference focus. "Spiritual healing ...
... video and information sharing ... ... release of the next phase on Beta site icyou ( http://www.icyou.com ... health video community provides the ability to post and,search healthcare videos, ...
... long agreed that girls have superior language abilities than boys, ... that may account for their differences. , For the ... Northwestern University and the University of Haifa show both that ... girls than in boys during language tasks, and that boys ...
Cached Medicine News:Health News:RealSelf.com Denies Lifestyle Lift's Trademark Claims and Files Countersuit 2Health News:Beauty.com Partners With Fashion Designer Jenni Kayne 2Health News:Beauty.com Partners With Fashion Designer Jenni Kayne 3Health News:Beauty.com Partners With Fashion Designer Jenni Kayne 4Health News:Researchers develop new tool to predict who will use microbicides 2Health News:Researchers develop new tool to predict who will use microbicides 3Health News:Spiritual Health Experts Speak at Chaplains Conference in Pittsburgh March 8-12 2Health News:Benefitfocus(R) Healthcare Video Portal Merges Community with Credibility 2Health News:Gender differences in language appear biological 2Health News:Gender differences in language appear biological 3
... biocompatible, flexible, one-piece artificial cornea (keratoprosthesis) designed ... cornea., ,The World Health Organisation (WHO) reports ... million people worldwide, however only 100,000 people ... is due to a combination of inadequate ...
A comprehensive CPT surgical, radiological and anesthesia coding reference....
PDA-version of the leading portable drug reference....
PDA format of the well-known standard antimicrobial reference....
Medicine Products: